Clinical Trials
15 trialsNCT07623798 2026-06-03
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Not yet recruiting
NCT07624513 2026-06-03
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 3 Not yet recruiting
NCT07601100 2026-06-01
IsaIberVD
Dana-Farber Cancer Institute
Phase 1/2 Not yet recruiting
NCT07614360 2026-05-29
DREAMM-16
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07609706 2026-05-27
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT07600151 2026-05-20
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Not yet recruiting
NCT07285239 2026-05-18
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT07513129 2026-04-21
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT07072585 2025-12-31
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group
Phase 2/3 Not yet recruiting
NCT07247097 2025-11-25
ELDORADO
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT06656221 2024-11-19
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Not yet recruiting